Profound Medical TULSA Procedure Superior in Penile Length, QoL in CAPTAIN Trial

Profound Medical Corp. announced new data from its Level 1 post-market CAPTAIN randomized controlled trial, comparing the TULSA Procedure with robotic radical prostatectomy for intermediate-risk prostate cancer. The TULSA Procedure showed no median change in penile length at 1 month, significantly outperforming robotic RP which resulted in a median 0.65 cm reduction. This new data, presented at the Society of Robotic Surgery Annual Meeting, builds on previous findings that demonstrated TULSA's superiority in preserving erectile function and urinary continence.